
|Videos|December 24, 2019
Targeting CD38 in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
4
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
5
































